[go: up one dir, main page]

DK3265085T3 - Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser - Google Patents

Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser Download PDF

Info

Publication number
DK3265085T3
DK3265085T3 DK16711733.2T DK16711733T DK3265085T3 DK 3265085 T3 DK3265085 T3 DK 3265085T3 DK 16711733 T DK16711733 T DK 16711733T DK 3265085 T3 DK3265085 T3 DK 3265085T3
Authority
DK
Denmark
Prior art keywords
treatment
methods
movement disorders
involuntary movement
abnormal involuntary
Prior art date
Application number
DK16711733.2T
Other languages
English (en)
Inventor
David Stamler
Michael Fangching Huang
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55590145&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3265085(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3265085T3 publication Critical patent/DK3265085T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Prostheses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK16711733.2T 2015-03-06 2016-03-07 Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser DK3265085T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562129616P 2015-03-06 2015-03-06
US201562175112P 2015-06-12 2015-06-12
US201562180012P 2015-06-15 2015-06-15
PCT/US2016/021238 WO2016144901A1 (en) 2015-03-06 2016-03-07 Methods for the treatment of abnormal involuntary movement disorders

Publications (1)

Publication Number Publication Date
DK3265085T3 true DK3265085T3 (da) 2022-10-03

Family

ID=55590145

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16711733.2T DK3265085T3 (da) 2015-03-06 2016-03-07 Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser

Country Status (24)

Country Link
US (9) US20160287574A1 (da)
EP (2) EP4140483A1 (da)
JP (3) JP6932641B2 (da)
KR (4) KR20230003264A (da)
CN (4) CN114796209A (da)
AU (2) AU2016229949B2 (da)
CA (2) CA3236214A1 (da)
CL (1) CL2017002223A1 (da)
DK (1) DK3265085T3 (da)
EA (1) EA201791977A1 (da)
ES (1) ES2927262T3 (da)
HK (1) HK1249860A1 (da)
HR (1) HRP20221106T1 (da)
HU (1) HUE059747T2 (da)
IL (3) IL288712B2 (da)
LT (1) LT3265085T (da)
MX (2) MX385368B (da)
PL (1) PL3265085T3 (da)
PT (1) PT3265085T (da)
RS (1) RS63647B1 (da)
SG (1) SG11201706959TA (da)
UA (1) UA129759C2 (da)
WO (1) WO2016144901A1 (da)
ZA (2) ZA201706131B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1212232A1 (en) 2012-09-18 2016-06-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN114796209A (zh) 2015-03-06 2022-07-29 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
CA3002074A1 (en) 2015-10-30 2017-05-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
WO2017221169A1 (en) * 2016-06-24 2017-12-28 Lupin Limited Premixes of deutetrabenazine
KR20190108149A (ko) 2017-01-27 2019-09-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3056612A1 (en) 2017-03-15 2018-09-20 Auspex Pharmaceuticals, Inc. Analogs of deutetrabenazine, their preparation and use
US20200179352A1 (en) * 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
BR112020005373A2 (pt) 2017-09-21 2020-09-24 Neurocrine Biosciences Inc. formulação de valbenazina em alta dosagem e composições, métodos e kits relacionados com valbenazina
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3077149A1 (en) 2017-10-10 2019-04-18 Neurocrine Biosciences, Inc. Methods for the administration of (s)-2-amino-3-methyl-butyric acid (2r,3r,11br)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2yl ester and salts thereof
RU2020114598A (ru) 2017-11-08 2021-12-09 Фореси Фармасьютикалс Ко., Лтд. Сложные эфиры дигидротетрабеназина
CA3097189A1 (en) 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
US20200345663A1 (en) * 2018-06-10 2020-11-05 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion
EP3790538A4 (en) * 2018-06-10 2021-06-30 Axsome Therapeutics, Inc. METHODS FOR MODULATING THE PLASMATIC LEVELS OF METABOLITES OF TETRABENAZINE BY MEANS OF BUPROPION
US20190374521A1 (en) * 2018-06-10 2019-12-12 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion
WO2020037022A1 (en) 2018-08-15 2020-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
HUE061801T2 (hu) 2018-10-18 2023-08-28 Oncopeptides Ab Deutérium-tartalmú vegyületek
KR20210114946A (ko) * 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진
CN109793745B (zh) * 2019-01-24 2021-05-25 遵义医科大学 阿司匹林在制备治疗异动症药物中的应用及其药物组合物
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP7709432B2 (ja) * 2019-10-22 2025-07-16 シンケイ セラピューティクス，インコーポレイテッド テトラベナジン経皮送達デバイス
US20220296585A1 (en) * 2020-06-10 2022-09-22 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
MX2022015742A (es) * 2020-06-10 2023-01-19 Auspex Pharmaceuticals Inc Formas farmaceuticas osmoticas que comprenden deutetrabenazina y metodos de uso de las mismas.
US20240207247A1 (en) * 2021-04-15 2024-06-27 Neurocrine Biosciences, Inc. Methods for the combined administration of deutetrabenazine and a cyp2d6 inhibitor
WO2022221551A1 (en) * 2021-04-15 2022-10-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
KR20250153211A (ko) 2023-02-10 2025-10-24 테바 파마슈티컬 인더스트리즈 리미티드 운동 장애 검출 및 평가
WO2025188830A1 (en) * 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) 1958-07-15 Method for preparing same
US2830993A (en) 1958-04-15 Quinolizine derivatives
US3045021A (en) 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
HU175890B (en) 1977-06-15 1980-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new 1,2,3,4,6,7-hexahydro-11-b-alpha-benzo-square bracket-a-square brecket closed-quinolyzine derivatives
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4316897A (en) 1980-09-10 1982-02-23 Hoffmann-La Roche Inc. Method of lowering serum prolactin
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
AU709704B2 (en) 1995-07-24 1999-09-02 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
GB9817028D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US7260823B2 (en) 2001-01-11 2007-08-21 Prime Research Alliance E., Inc. Profiling and identification of television viewers
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
EP1104760B1 (en) 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
EP1134290A3 (en) 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US20020183553A1 (en) 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
BR0214742A (pt) 2001-12-05 2004-09-14 Wyeth Corp Polimorfo cristalino de cloridrato de venlafaxina e métodos para sua preparação
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
AU2004249211A1 (en) 2003-06-16 2004-12-29 Andrx Pharmaceuticals, Llc Oral extended-release composition
DE602004014635D1 (de) 2003-11-21 2008-08-07 Memory Pharmaceutical Corp Zusammensetzungen enhaltend l-typ-calciumcanalblockern und cholinesterase-hemmern
US7367953B2 (en) 2003-11-26 2008-05-06 Ge Medical Systems Global Technology Company Method and system for determining a period of interest using multiple inputs
US20100018408A1 (en) 2004-02-06 2010-01-28 Lassota Zbigniew G Brew basket assembly and brewer
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
US20070196396A1 (en) 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
CA2591948C (en) 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP2338881A1 (en) 2005-02-23 2011-06-29 Prexa Pharmaceuticals, Inc. Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications
CA2613631A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
US20080033011A1 (en) 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
EP1991522B1 (en) 2006-02-17 2016-05-18 imphar Aktiengesellschaft Deuterated catecholamine derivatives and medicaments comprising said compounds
EP2604290A3 (en) 2006-05-02 2013-07-10 The Trustees of The University of Pennsylvania Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
HU227610B1 (en) 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
AU2007306316B2 (en) 2006-10-12 2011-10-27 Kyushu University Use of modified cyclosporins
EA018378B1 (ru) 2006-11-08 2013-07-30 Ньюрокрайн Байосайенсиз, Инк. ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EP2420505A1 (en) 2006-11-21 2012-02-22 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses
US20100204258A1 (en) 2007-03-12 2010-08-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
SI2125698T1 (sl) 2007-03-15 2016-12-30 Auspex Pharmaceuticals, Inc. Devterirani d9-venlafaksin
US7897768B2 (en) 2007-06-08 2011-03-01 General Electric Company Method for making tetrabenazine compounds
CA2729006C (en) 2007-06-29 2017-01-31 Clarencew Pty Ltd Treatment or prophylaxis of neurological or neuropsychiatric disorders via ocular administration
US7902364B2 (en) 2007-11-29 2011-03-08 General Electric Company Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
WO2009124357A1 (en) 2008-04-10 2009-10-15 Malvin Leonard Eutick Fast dissolving oral formulations for critical drugs
US9012471B2 (en) 2008-04-11 2015-04-21 The Trustees Of Columbia University In The City Of New York Glucose metabolism modulating compounds
JP5207852B2 (ja) 2008-06-30 2013-06-12 三洋電機株式会社 太陽電池及びその製造方法
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US20100018969A1 (en) 2008-07-24 2010-01-28 Feature Foods, Inc. Packaging for food products
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
CA2972242A1 (en) 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20100113496A1 (en) 2008-09-25 2010-05-06 Auspex Pharmaceuticals, Inc. Piperidine modulators of vmat2
EP2396312A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
CA2771539A1 (en) * 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
US8658236B2 (en) * 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
EP2539347A2 (en) 2010-02-24 2013-01-02 Auspex Pharmaceuticals, Inc. Trimethoxyphenyl inhibitors of tyrosine kinase
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
CN103003275A (zh) 2010-06-01 2013-03-27 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
US9321095B2 (en) 2010-06-30 2016-04-26 General Electric Company Apparatuses and methods for cutting porous substrates
US9676810B2 (en) 2010-07-08 2017-06-13 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2012081031A1 (en) 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
RU2013135224A (ru) 2011-01-20 2015-03-10 Бионевиа Фармасьютикалс Инк. Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
US20130332829A1 (en) 2011-01-22 2013-12-12 Filippo Costanzo Dynamic 2d and 3d gestural interfaces for audio video players capable of uninterrupted continuity of fruition of audio video feeds
MX2013015270A (es) 2011-06-24 2014-03-31 Direct Tv Group Inc Metodo y sistema para obtener datos de visualizacion y proporcionar recomndaciones de contenido a un decodificador de señales digitales.
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
KR101362482B1 (ko) 2012-01-31 2014-02-12 한국과학기술연구원 테트라베나진과 다이하이드로테트라베나진의 제조방법
EP2827856A4 (en) 2012-03-23 2016-03-09 Cardero Therapeutics Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISEASES
HK1212232A1 (en) 2012-09-18 2016-06-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN102936246A (zh) 2012-11-08 2013-02-20 江苏暨明医药科技有限公司 丁苯那嗪的合成方法
MX2015009719A (es) 2013-01-31 2016-08-08 Auspex Pharmaceuticals Inc Inhibidores benzoquinolona de vmat2.
EP3049087A4 (en) 2013-09-27 2017-05-24 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2015077521A1 (en) 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2015077520A1 (en) 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Methods of treating abnormal muscular activity
EP3424504A1 (en) 2013-12-03 2019-01-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
CA2936823A1 (en) 2014-01-27 2015-07-30 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
MX2016010213A (es) 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
CN114796209A (zh) 2015-03-06 2022-07-29 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
CN117915901A (zh) * 2021-04-15 2024-04-19 纽罗克里生物科学有限公司 氘代丁苯那嗪和cyp2d6抑制剂的联合施用方法

Also Published As

Publication number Publication date
AU2016229949B2 (en) 2021-04-08
US11446291B2 (en) 2022-09-20
ZA201706131B (en) 2019-09-25
PT3265085T (pt) 2022-09-05
HK1248609A1 (en) 2018-10-19
UA129759C2 (uk) 2025-07-30
HRP20221106T1 (hr) 2022-11-25
JP2022109989A (ja) 2022-07-28
US11357772B2 (en) 2022-06-14
WO2016144901A1 (en) 2016-09-15
CA2978006C (en) 2024-06-25
RS63647B1 (sr) 2022-11-30
SG11201706959TA (en) 2017-09-28
HK1249860A1 (zh) 2018-11-16
CA2978006A1 (en) 2016-09-15
IL288712B1 (en) 2023-09-01
CN107624067A (zh) 2018-01-23
MX2017011459A (es) 2018-04-24
IL288712A (en) 2022-02-01
US20210379051A1 (en) 2021-12-09
HUE059747T2 (hu) 2022-12-28
IL254121A0 (en) 2017-10-31
IL288712B2 (en) 2024-01-01
US20210275517A1 (en) 2021-09-09
IL254121B (en) 2022-01-01
EP4140483A1 (en) 2023-03-01
MX2021009830A (es) 2021-09-08
CN114796209A (zh) 2022-07-29
EP3265085A1 (en) 2018-01-10
AU2021204740A1 (en) 2021-08-05
US20240316035A1 (en) 2024-09-26
US20170326131A1 (en) 2017-11-16
US20170151227A1 (en) 2017-06-01
AU2021204740B2 (en) 2024-10-17
ES2927262T3 (es) 2022-11-03
AU2016229949A1 (en) 2017-09-21
CN114767672A (zh) 2022-07-22
US11564917B2 (en) 2023-01-31
KR20240049625A (ko) 2024-04-16
JP7066902B2 (ja) 2022-05-13
KR20170122820A (ko) 2017-11-06
US20180064701A1 (en) 2018-03-08
KR102335744B1 (ko) 2021-12-07
JP2021183630A (ja) 2021-12-02
KR20230003264A (ko) 2023-01-05
EA201791977A1 (ru) 2018-01-31
JP2018507248A (ja) 2018-03-15
US20160287574A1 (en) 2016-10-06
NZ735000A (en) 2024-02-23
ZA201902108B (en) 2021-09-29
US11648244B2 (en) 2023-05-16
US12016858B2 (en) 2024-06-25
CL2017002223A1 (es) 2018-06-08
IL305352A (en) 2023-10-01
EP3265085B1 (en) 2022-07-20
KR102528845B1 (ko) 2023-05-08
US20180318281A1 (en) 2018-11-08
US10959996B2 (en) 2021-03-30
KR20210149246A (ko) 2021-12-08
MX385368B (es) 2025-03-18
JP6932641B2 (ja) 2021-09-08
US20210145820A1 (en) 2021-05-20
CA3236214A1 (en) 2016-09-15
CN114788824A (zh) 2022-07-26
PL3265085T3 (pl) 2022-11-07
LT3265085T (lt) 2022-11-10

Similar Documents

Publication Publication Date Title
DK3265085T3 (da) Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3261640T3 (da) 5ht-agonister til behandling af epilepsilidelser
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3851537T5 (da) Behandling af hyperbilirubinæmi
DK3285803T3 (da) Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3936130T3 (da) Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser
DK3433266T3 (da) Fremgangsmåder til behandling af mitokondrieforstyrrelser
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3288577T3 (da) Adiponectin-peptidomimetika til behandling af øjenlidelser
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
IL255185A0 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3307267T3 (da) Behandling af multipel sklerose
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3848028T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3302573T3 (da) Sammensætning til behandlingen af hjernelæsioner
DK3049100T3 (da) Modificerede fibroblastvækstfaktorer-1 til behandling af øjenlidelser
DK3458067T3 (da) Behandling af neurologiske lidelser